Reading the tape
NASDAQ: TWST
Twist Bioscience Corporation
Healthcare · Medical - Diagnostics & Research
Market Cap
$3.45B
52w High
$66.06
52w Low
$23.30
P/E
-42.66
Volume
2.58M
Outstanding Shares
61.31M
Price vs Fundamentals
Why The Stock Is Moving
Fundamentals are supporting the moveModerate confidence
1Y Price: 56.39%Revenue (TTM): 17.77%FCF (TTM): -45.12%P/S: 43rd pct
What changed
The stock rose 56.39% over the last year. Revenue grew 17.77% over the trailing twelve months. Operating margin moved from -57.86% to -33.9%. Free cash flow declined 45.12% over the trailing twelve months.
What the market seems to be pricing
The stock move broadly lines up with stronger business momentum, and the shares are still only around the 43rd percentile of their historical P/S range.
What would invalidate this read
Operating margin is at -33.9%. Revenue grew 17.77% — this thesis depends on that trajectory holding. Despite the price move, free cash flow fell 45.12%, which is worth watching as a leading indicator of future pressure. If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.
Company profile
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products.
CEOEmily Marine Leproust
SectorHealthcare
IndustryMedical - Diagnostics & Research
Employees923
IPO dateOct 31, 2018
Valuation
Forward P/E—
EV/EBITDA-31.43
Enterprise value$1.64B
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth19.31%
Gross margin52.07%▲19.04%vs FY2024
Operating margin-33.9%▲48.72%vs FY2024
ROE-16.42%▲62.81%vs FY2024
Analyst consensus
RatingBuy
Target price$55.67▼0.93%
10
Buy
2
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Aug 3, 2026
Q3 FY26 · EPS est -$0.45 · Revenue est $113.36M
View